Karmele Mujika - Publications

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Journal: Cancer

Published: November 11, 2025

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.

Journal: The Lancet. Oncology

Published: June 30, 2025

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 12, 2025

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study.

Journal: Melanoma research

Published: February 07, 2025

A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.

Journal: British journal of cancer

Published: November 28, 2022

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.

Journal: Pigment cell & melanoma research

Published: November 27, 2022

Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).

Journal: Melanoma research

Published: June 28, 2022

SEOM clinical guideline for the management of cutaneous melanoma (2020).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 02, 2020

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Journal: Melanoma management

Published: December 25, 2019

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.

Journal: PloS one

Published: November 19, 2019

Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.

Journal: Molecular oncology

Published: October 12, 2019

The Circulating Transcriptome as a Source of Biomarkers for Melanoma.

Journal: Cancers

Published: November 15, 2018